Compare International Business Machines Corp (IBM) vs Teladoc Health Inc (TDOC) Price & Performance

IBM stock trades at $227.44, up 3.14% with recent momentum driven by positive sentiment in the consulting sector following Accenture's strong earnings. The company shows solid fundamentals with 2025 revenue of $67.54B and net income of $10.59B, though technical indicators suggest bearish momentum with the stock trading near resistance at $230. Recent developments include the self-hosted deployment option for IBM Bob AI platform, enhancing enterprise AI sovereignty capabilities.

IBM presents a mixed investment case with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus price target of $255.50 offering 12% upside potential. However, bearish technical signals, recent earnings miss in Q2 2026, and increased investing cash outflows (-$10.3B in 2025) present near-term headwinds. The stock's valuation at 20.13 P/E appears reasonable given the company's hybrid cloud and AI consulting growth trajectory.

Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.

TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.